MedTrace Logo

Nicotinamide Riboside in Hospitalized Patients

NCT04110028 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2024-05-20

No results posted yet for this study

Summary

Patients will receive oral nicotinamide riboside or placebo and clinical and paraclinical outcome will be determined

Conditions

Interventions

DRUG

Nicotinamide riboside

Nicotinamide riboside in different doses

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • ChromaDex, Inc.

    collaborator INDUSTRY

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Arne Søraas, PhD · Oslo University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2022-12-01
Completion
2023-12-01

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04110028 on ClinicalTrials.gov